Prostatype Genomics AB (PROGEN) - Net Assets
Based on the latest financial reports, Prostatype Genomics AB (PROGEN) has net assets worth Skr36.48 Million SEK (≈ $3.93 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr43.84 Million ≈ $4.72 Million USD) and total liabilities (Skr7.36 Million ≈ $791.62K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Prostatype Genomics AB to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr36.48 Million |
| % of Total Assets | 83.22% |
| Annual Growth Rate | N/A |
| 5-Year Change | 18.31% |
| 10-Year Change | N/A |
| Growth Volatility | 86.78 |
Prostatype Genomics AB - Net Assets Trend (2015–2024)
This chart illustrates how Prostatype Genomics AB's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Prostatype Genomics AB for the complete picture of this company's asset base.
Annual Net Assets for Prostatype Genomics AB (2015–2024)
The table below shows the annual net assets of Prostatype Genomics AB from 2015 to 2024. For live valuation and market cap data, see Prostatype Genomics AB market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr33.47 Million ≈ $3.60 Million |
+35.64% |
| 2023-12-31 | Skr24.67 Million ≈ $2.66 Million |
-5.65% |
| 2022-12-31 | Skr26.15 Million ≈ $2.81 Million |
-27.17% |
| 2021-12-31 | Skr35.91 Million ≈ $3.86 Million |
+26.92% |
| 2020-12-31 | Skr28.29 Million ≈ $3.04 Million |
+231.02% |
| 2018-12-31 | Skr8.55 Million ≈ $919.74K |
+37.34% |
| 2017-12-31 | Skr6.22 Million ≈ $669.69K |
-58.31% |
| 2016-12-31 | Skr14.93 Million ≈ $1.61 Million |
+1230.75% |
| 2015-12-31 | Skr-1.32 Million ≈ $-142.07K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Prostatype Genomics AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4171957000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr670.00K | 2.00% |
| Other Comprehensive Income | Skr-150.89 Million | -450.83% |
| Other Components | Skr183.69 Million | 548.83% |
| Total Equity | Skr33.47 Million | 100.00% |
Prostatype Genomics AB Competitors by Market Cap
The table below lists competitors of Prostatype Genomics AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cipta Selera Murni Pt
JK:CSMI
|
$4.83 Million |
|
Strategem Capital Corp
V:SGE
|
$4.83 Million |
|
Pittler Maschinenfabrik AG
F:PIT
|
$4.83 Million |
|
Chiangmai Rimdoi Public Company Limited
BK:CRD
|
$4.83 Million |
|
Global Sukses Solusi Tbk PT
JK:RUNS
|
$4.83 Million |
|
Kokoh Inti Arebama Tbk
JK:KOIN
|
$4.83 Million |
|
Golden Sky Minerals Corp
V:AUEN
|
$4.83 Million |
|
Sawang Export Public Company Limited
BK:SAWANG
|
$4.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prostatype Genomics AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 24,674,000 to 33,469,000, a change of 8,795,000 (35.6%).
- Net loss of 41,051,000 reduced equity.
- New share issuances of 66,151,000 increased equity.
- Other comprehensive income increased equity by 8,759,000.
- Other factors decreased equity by 25,064,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-41.05 Million | -122.65% |
| Share Issuances | Skr66.15 Million | +197.65% |
| Other Comprehensive Income | Skr8.76 Million | +26.17% |
| Other Changes | Skr-25.06 Million | -74.89% |
| Total Change | Skr- | 35.64% |
Book Value vs Market Value Analysis
This analysis compares Prostatype Genomics AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr-0.05 | Skr0.76 | x |
| 2016-12-31 | Skr0.53 | Skr0.76 | x |
| 2017-12-31 | Skr0.22 | Skr0.76 | x |
| 2018-12-31 | Skr613.52 | Skr0.76 | x |
| 2020-12-31 | Skr40.89 | Skr0.76 | x |
| 2021-12-31 | Skr24.45 | Skr0.76 | x |
| 2022-12-31 | Skr6.94 | Skr0.76 | x |
| 2023-12-31 | Skr7.17 | Skr0.76 | x |
| 2024-12-31 | Skr11.14 | Skr0.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prostatype Genomics AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -122.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20628.64%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-122.65%) is below the historical average (-87.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -11320.24% | 0.02x | 0.00x | Skr-11.36 Million |
| 2016 | -31.80% | -95.02% | 0.25x | 1.32x | Skr-6.24 Million |
| 2017 | -149.74% | -5757.43% | 0.01x | 3.17x | Skr-9.94 Million |
| 2018 | -99.99% | -11535.30% | 0.00x | 2.06x | Skr-9.40 Million |
| 2020 | -61.53% | -2545.52% | 0.02x | 1.19x | Skr-20.24 Million |
| 2021 | -43.53% | -156297.58% | 0.00x | 1.12x | Skr-19.22 Million |
| 2022 | -111.23% | -4258.71% | 0.02x | 1.18x | Skr-31.70 Million |
| 2023 | -167.93% | -3055.68% | 0.03x | 1.99x | Skr-43.90 Million |
| 2024 | -122.65% | -20628.64% | 0.00x | 1.25x | Skr-44.40 Million |
Industry Comparison
This section compares Prostatype Genomics AB's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $176,606,681
- Average return on equity (ROE) among peers: -23.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prostatype Genomics AB (PROGEN) | Skr36.48 Million | 0.00% | 0.20x | $4.83 Million |
| AroCell AB (AROC) | $80.41 Million | -20.15% | 0.14x | $13.39 Million |
| Devyser Diagnostics AB (DVYSR) | $431.44 Million | -10.65% | 0.16x | $168.47 Million |
| Immunovia publ AB (IMMNOV) | $243.80 Million | -59.49% | 0.23x | $14.70 Million |
| SenzaGen AB (SENZA) | $107.79 Million | -25.34% | 0.03x | $17.21 Million |
| Vimian Group AB (VIMIAN) | $19.59 Million | -4.03% | 0.70x | $1.70 Billion |
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doct… Read more